InSilico Medicine Cayman TopCo (HKG:3696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
61.95
-0.90 (-1.43%)
At close: Feb 27, 2026
77.00%
Market Cap 35.31B
Revenue (ttm) 420.77M
Net Income (ttm) -348.07M
Shares Out 569.97M
EPS (ttm) -4.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 997,050
Average Volume 2,069,028
Open 62.50
Previous Close 62.85
Day's Range 60.50 - 63.50
52-Week Range 29.98 - 80.90
Beta n/a
RSI 50.80
Earnings Date n/a

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ... [Read more]

Sector Technology
Founded 2014
Country Cayman Islands
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3696
Full Company Profile

Financial Performance

In 2024, HKG:3696's revenue was $85.83 million, an increase of 67.71% compared to the previous year's $51.18 million. Losses were -$17.10 million, -91.92% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.